TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.
personDouglas Adkins, MD
Washington University School of Medicine
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
24.5¢ |
Change
-0.005(2.00%) |
Mkt cap ! $359.6M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.0¢ | 24.3¢ | $239.9K | 976.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1678 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 138979 | 4 |
View Market Depth
| Last trade - 16.10pm 17/09/2025 (20 minute delay) ? |
| IMM (ASX) Chart |